See more : Malu Paper Mills Limited (MALUPAPER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of EQRx, Inc. (EQRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EQRx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- ARIS INTERNATIONAL LTD. (ARISINT.BO) Income Statement Analysis – Financial Results
- Priority Aviation, Inc. (PJET) Income Statement Analysis – Financial Results
- Noble Group Limited (NOBGY) Income Statement Analysis – Financial Results
- Graphano Energy Ltd. (GEL.V) Income Statement Analysis – Financial Results
- Kopin Corporation (0JRR.L) Income Statement Analysis – Financial Results
EQRx, Inc. (EQRX)
About EQRx, Inc.
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 228.50M | 118.11M | 224.39M | 3.44K |
| General & Administrative | 127.38M | 78.27M | 25.69M | 10.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 127.38M | 78.27M | 25.69M | 10.44K |
| Other Expenses | -65.00K | 87.05M | 0.00 | 0.00 |
| Operating Expenses | 355.88M | 196.38M | 250.08M | 25.52K |
| Cost & Expenses | 355.88M | 196.38M | 250.08M | 25.52K |
| Interest Income | 25.15M | 436.00K | 97.00K | 0.00 |
| Interest Expense | 25.15M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -161.70M | -7.70M | 338.00K | 171.86K |
| EBITDA | -355.88M | -196.38M | -249.74M | -11.65K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -355.88M | -196.38M | -250.08M | -13.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 186.79M | 96.37M | 97.00K | -11.65K |
| Income Before Tax | -169.09M | -100.01M | -249.98M | -25.52K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -374.58M | -9.32M | -97.00K | -11.65K |
| Net Income | 205.49M | -90.69M | -249.89M | -25.52K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.43 | -0.28 | -0.80 | -5.99 |
| EPS Diluted | 0.43 | -0.28 | -0.80 | -5.99 |
| Weighted Avg Shares Out | 474.30M | 324.01M | 311.50M | 4.26K |
| Weighted Avg Shares Out (Dil) | 474.30M | 324.01M | 311.50M | 4.26K |
Calling All EQRx, Inc. (EQRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
EQRX Shareholder Investigation: Robbins LLP Reminds Shareholders it is Investigating EQRx, Inc. on behalf of Shareholders
Should You Buy EQRx (EQRX) Ahead of Earnings?
EQRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of EQRx, Inc. - EQRX
Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines
Best Penny Stocks To Watch After Fitch Downgrade? 3 For Your List
EQRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of EQRx, Inc. Is Fair to Shareholders
Revolutin Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D
Source: https://incomestatements.info
Category: Stock Reports